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Abstract A new site of serine phosphorylation (Ser-1035/1037) has been identified in the kinase domain of the insulin receptor. Mutant receptors 
missing these two serines were expressed in Chinese hamster ovary ceils overexpressing protein kinase C~t. These mutant receptors lacked a phorbol 
ester-stimulated phosphoserine containing tryptic peptide as demonstrated by both high p rcentage polyacrylamide/urea g l el ctrophoresis and 
two-dimensional tlc. Moreover, a synthetic peptide with the sequence of this tryptic peptide was phosphorylated byisolated protein kinase Cot and 
co-migrated with the phosphopeptide from in viv  labeled receptor. These results indicate that serine-1035 and/or 1037 in the kinase domain of the 
insulin receptor are phosphorylated in r sponse to activation of protein kinase C~. 
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1. Introduction 
Insulin induces extensive tyrosine phosphorylation of the 
cytoplasmic domain of the fl-subunit of its receptor (IR) with 
at least six tyrosines being phosphorylated, three in the kinase 
domain, one in the juxtamembrane region and two in the car- 
boxy tail of the receptor [1-3]. This tyrosine phosphorylation 
appears to greatly activate the intrinsic tyrosine kinase activity 
of the receptor to phosphorylate various endogenous sub- 
strates. Two tyrosine residues in the kinase domain of the 
receptor (Tyr-1162 and 1163) appear to primarily contribute to 
this activation of the receptor kinase. In addition to this tyro- 
sine phosphorylation, the IR fl-subunit is also extensively 
phosphorylated on serine residues and to a limited extent on 
threonine [4,5]. Two serines (Ser-1305/1306) and one threonine 
(Thr- 1348) in the carboxy tail of the receptor have been found 
to be phosphorylated in vitro by purified protein kinase C 
(PKC) and in vivo after activation of PKC [6-9]. However, the 
phosphorylations of these serines and the threonine appear to 
have little affect on the receptor kinase activity. 
The Ser/Thr phosphorylation f the receptor is of potential 
importance in the negative r gulation of the IR tyrosine kinase 
activity that has been observed in the receptor from many 
non-insulin-dependent iabetic patients with insulin resistance 
[10]. It could also be involved in the desensitization f the 
receptor, either in response to insulin itself or through the 
activation of other signaling systems by various counter regula- 
tory hormones uch as tumor necrosis factor or glucagon 
[11-13]. An inhibition of the receptor's intrinsic tyrosine kinase 
activity has been demonstrated in several such systems. In one, 
Chinese hamster ovary (CHO) cells overexpressing protein ki- 
nase Ca and the IR, activation of PKC was shown to greatly 
increase the serine phosphorylation f the receptor and to in- 
hibit the ability of insulin to stimulate the tyrosine phosphoryl- 
ation of its endogenous substrate, IR substrate-1 (IRS-1) [ 4]. 
In the present studies we have made use of this system to try 
to identify new serine phosphorylation sites in the IR. One such 
site that has now been identified (serine-1035 and/or 1037) is 
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in the kinase domain of the receptor, close to a region which 
is critical for ATP binding. 
2. Experimental 
2.1. Site-directed mutagenesis and expression ofmutant receptors 
A 2.4 kb BamHI-XbaI fragment isolated from the human IR cDNA 
[15] was subcloned in to pBluescript II SK plasmid(Stratagene) and
used as the template to g nerate mutant S1035/7A and 1035/7D. O1- 
igonucleotide-directed mutagenesis was carded out as described by 
Kunkel et al. [16]. Chemically synthesized oligonucleotides used for 
mutagenesis are as follows (the mismatched bases are underlined): 
S 1°35rTA 5'-CGGTCAACGAGGCAGCCGCTCTCCGAGAGC'-(de- 
stroy P/el site); S 1°35n° 5'-CGCJ'TCAACt3-AGGATGCCGATCTCC- 
GAGAGC-" (new BsaBI site). The recombinant plasmid co~ining the 
mutant IR cDNA was used to transform DH5~ and the mutations were 
identified by both restriction enzyme analysis and DNA sequencing. 
The mutant cDNAs were subeloned intothe SR~ expression vector [17] 
and transfected into CHO/PKCct cells as previously described [18]. 
Positive colonies were selected by Western with anti-phosphotyrosine 
antibody RC-20 (Transduction Laboratories) nd confirmed by blot- 
ting with anti-IR antibodies. 
2.2. In vitro phosphorylation f the synthetic peptide 
The synthetic peptide, TVNESASLR, corresponding t  amino acids 
1031 to 1039 deduced from human IR cDNA was phosphorylated by
immunoprecipitated protein kinase C~t. The reaction buffer (100/zl) 
contained 20 mM Tris-HC1, pH 7.5, 20 mM MgC12, 1 mM C~tCI2. 5/zM 
ATP, 20/zg synthetic peptide, 10/zM TPA, 0.2 mg/ml phosphatidyl- 
serine in Triton X-100 mixed micelles, and PKC~ bound to anti-PKC 
monocolonal antibody (Amersham) coated protein G-Sepharose. After 
20 rain at 24°C, the reaction wasterminated by centrifugation a d the 
supernatant was transferred to a fresh tube, treated with activated 
charcoal, and subjected to high percentage PAGE analysis. 
2.3. Tryptic digestion, high percentage PAGE, and two-dimensional 
phosphopeptide mapping 
Tryptic digestion f 32p-labeled human IR was conducted as de- 
scribed by Luo et al. [19]. In brief, the radiolabled IR was first treated 
with a tyrosine phosphatase to r move any phosphotyrosine present 
[18] and then subjected o SDS-PAGE, blotted to nitrocellulose mem- 
brane, and digested with 20/zg TPCK-treated trypsin (Worthington) 
in a freshly prepared 50 mM ammonium bicarbonate buffer at 37°C 
for 18 h. An additional 10/zg of TPCK-treated trypsin was added and 
the reaction mixture was incubated for a further 6 . The tryptic digests 
were lyophilized, resuspended i  a gel loading buffer containing 
0.125 M Tris-HCl, pH 6.8, and 6 M urea, with Bromophenol blue. High 
percentage alkaline polyaerylamide gels were prepared according to 
West et al. [20]. Electrophoresis was carried out overnight at a constant 
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Fig. 1. Autoradiogram of 32P-labeled tryptic peptides separated by high 
percentage/urea g l electrophoresis. (A) Phosphorylation f a synthetic 
peptide and co-migration with an IR tryptic phosphopeptide. IR, iso- 
lated from in vivo labeled cells treated with or without 1.6 gM TPA, 
was digested with trypsin as described inthe Methods. A synthesized 
9-mer peptide was phosphorylated by PKC in vitro. The resulting 
phosphopeptides were analyzed by high percentage polyacrylamide/ 
urea gel electrophoresis. (B) Comparison of the tryptic phosphopep- 
tides of the wild-type and mutant Ser1035/7A IR. IR was isolated from 
TPA-treated in vivo labeled cells expressing either the native or mu ant 
IR, digested with trypsin and analyzed by gel electrophoresis. 
current of 10 mA. The gel was dried under vacuum andautoradiogra- 
phed. For two-dimensional tryptic phosphopeptide mapping, the lyo- 
philized sample was re uspended in 2-3 gl water containing 5 mg/ml 
DNP-lysine and 1 mg/ml xylene cyanol FF and spotted on a TLC plate 
[21]. First-dimension separation was carried out at pH 3.5 in glacial 
acetic acid/pyridine/water (10:1:189) [2 ]. The electrophoresis was 
conducted at 400 V for 2 h. The second dimensional thin-layer chrom- 
atography was carried out for 8-10 h in chromatography buffer con- 
taining n-butanol/pyridine/glacial acetic acid/water (75 : 50:15 : 60) [21]. 
The plates were dried an autoradiographed. 
3. Results and discussion 
Tryptic digests of IR from TPA-stimulated CHO cells over- 
expressing both PKC~ and IR (CHO/PKC/IR) indicated that 
at least 7 phosphoserine containing peptides were generated 
(Fig. 1A). Attempts to sequence these phosphopeptides were 
unsuccessful. However, the amino acid compositions for some 
of these peptides were obtained. The amino acid composition 
of one of the peptides (Ala, Asp, Thr, Ser, Leu, Yal, and Ile in 
a ratio of 1 : 2:1 : 2: 1.3 :0.8 : 0.7), matched the amino acid com- 
position of a tryptic fragment corresponding to residues 1031 
to 1039 in the IR. This peptide, which has a sequence of TVNE- 
SASLR, is quite interesting in that it is very close to the ATP 
binding region of the receptor. Ser-1037 is also conserved 
among all the members of the IR family. Finally, Ahn et al. had 
previously reported that a larger peptide (which encompasses 
this peptide) from IR phosphorylated in vitro with PKC also 
contained phosphoserine [9]. 
A peptide corresponding to the amino acid sequence 1031 to 
1039 of the IR was chemically synthesized and checked for its 
ability to be phosphorylated by PKCct in vitro. This peptide 
was found to be phosphorylated by PKC~ and to co-migrate 
with one of the in vivo labeled, TPA-stimulated phosphopep- 
tides of the receptor (Fig. 1A). To further test whether the two 
serines in this region of the IR were phosphorylated, site- 
directed mutagenesis was used to replace these residues in the 
IR with either alanine (Ser 1035/7A) or aspartate (S1035/7D). The 
latter mutant was made on the basis of the hypothesis that 
aspartate may mimic the affect of phosphorylation at these 
residues by introducing a negative charge at the site [22]. Stable 
cell lines overexpressing either wild-type or mutant receptors 
and PKC= were generated and characterized. Both mutant 
receptors appeared to be processed normally as judged from 
the fraction of proreceptor and the size of their fl-subunits 
(Fig. 2A). Lines expressing two different levels of mutant IR 
Ser-1035/7D were studied (Fig. 2A). 
To further test whether serines 1035 and 1037 in the human 
IR are sites of TPA-stimulated phosphorylation i vivo, 
phosphopeptide mapping of the wild-type and the mutant 
(S ~°35ng) receptors from in vivo labeled TPA-treated cells was 
carried out. The mutant IR exhibited the same tryptic peptide 
pattern as the wild-type IR except hat one of the phosphopep- 
tide bands was missing (Fig. 1B). The in vitro labeled synthetic 
peptide migrated to the same location as this missing 
phosphopeptide band (Fig. 1B). The tryptic peptide patterns of 
the wild-type and mutant IR were also studied by two-dimen- 
sional phosphopeptide mapping. Again, the mutant IR showed 
the same tryptic pattern as the wild-type IR except hat one of 
the phosphopeptides was missing (Fig. 3B). These results dem- 
onstrate that serines-1035 and/or 1037 in the kinase domain of 
the IR are phosphorylated in TPA-stimulated cells, presumably 
by PKCa since the peptide containing these residues could also 
be phosphorylated in vitro by isolated PKC~. 
To determine whether the mutations affected the IR tyrosine 
kinase activity, the receptor from insulin-treated cells was im- 
munoprecipitated and blotted with anti-phosphotyrosine a ti- 
bodies. The extent of IR autophosphorylation c rrelated with 
the amount of each receptor present (Fig. 2B). The ability of 
these mutant receptors to phosphorylate an exogenous ub- 
strate, poly (Glu, Tyr), also appeared not to differ significantly 
from the wild-type receptor (data not shown). To measure 
the ability of these different receptors to phosphorylate an 
endogenous substrate, anti-phosphotyrosine pr cipitable Pl 
3-kinase activity was examined in cells expressing the different 
receptors. Insulin stimulated a comparable increase in this 
amount of activity in the different cells (legend to Fig. 4). Since 
prior studies of cells expressing the wild-type receptor have 
shown that TPA pretreatment caused an inhibition of this re- 
sponse [8], we examined whether the responses mediated via the 
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Fig. 2. Expression of the wild-type and mutant IRs. (A) Immunoblot- 
ting of the IR with anti-receptor antibody. Anti-IR immunoprecipitates 
from lysates of insulin-treated CHO/PKC cells transfected with expres- 
sion vector alone (1), expression vector encoding the wild-type IR (2),or 
the mutants Set-1035/7A (3) or Ser1035/7D (4,5) were electrophoresed 
on 10% polyacrylamide SDS gel, transferred to nitrocellulose and im- 
munoblotted with a monoclonal antibody to the fl-subunit of the IR. 
(B) Anti-phosphotyrosine immunoblotting. The same blot as in panel 
A was probed with anti-phosphotyrosine antibody RC20. 
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Fig. 3. Comparison of the tryptic phosphopeptides of the wild-type (A) and mutant Ser1035/7A IR (B) by two-dimensional tic. IR from TPA- 
stimulated, metabolically abeled cells was precipitated, igested with trypsin and analyzed as described in section 2. 
mutant receptors were similarly inhibited. A 60% decrease in 
the insulin-stimulated response was observed in the cell lines 
overexpressing either mutant IR 1035/7A or mutant 1035/7D, 
a value similar to that found for cells overexpressing the wild- 
type receptor (Fig. 4). 
In summary, the present studies have identified the first 
serine phosphorylation sites in the kinase domain of the insulin 
receptor. Surprisingly, mutation of these residues to either a 
neutral amino acid, alanine, or a negatively charged amino 
acid, aspartate, did not significantly affect the tyrosine kinase 
activity of the receptor. Moreover, these mutant receptors till 
exhibited a TPA mediated inhibition of an insulin-stimulated 
response, the increase in anti-phosphotyrosine precipitable PI 
3-kinase activity. These results indicate that the phosphoryla- 
tion of these serine residues in the kinase domain do not medi- 
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Fig. 4. TPA-mediated inhibition of the insulin-stimulated increase in 
anti-phosphotyrosine-precipitable PI 3-kinase. Cells expressing wild- 
type (WT), mutant S1035/7A or mutant S1035/7D IR were treated with 
insulin in the presence or absence of TPA, lysed and the lysates were 
adsorbed with anti-phosphotyrosine antibodies. The amount of PI 
3-kinase activity in the precipitates was measured and the activity in the 
absence of TPA was defined as 100%. These values were 1780, 1830 and 
2130 for the cells expressing the wild-type, mutant S1035/7A and S 1035/ 
7D IR, respectively. 
ate the TPA induced inhibition of this response although it is 
possible that the phosphorylation of these serines may have 
other effects on receptor functions. 
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